US 12,295,640 B2
Cancer immunotherapy by radiofrequency electrical membrane breakdown (RF-EMB)
Gary M. Onik, Fort Lauderdale, FL (US); and James A. Miessau, Branford, CT (US)
Assigned to ImmunSys, Inc., Fort Lauderdale, FL (US)
Filed by ImmunSYS, Inc., Fort Lauderdale, FL (US)
Filed on Nov. 23, 2020, as Appl. No. 17/101,434.
Application 17/101,434 is a continuation of application No. 15/102,120, granted, now 10,849,678, previously published as PCT/US2014/068774, filed on Dec. 5, 2014.
Application 15/102,120 is a continuation of application No. 14/451,333, filed on Aug. 4, 2014, granted, now 10,154,869, issued on Dec. 18, 2018.
Claims priority of provisional application 61/912,172, filed on Dec. 5, 2013.
Prior Publication US 2021/0177491 A1, Jun. 17, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61B 18/14 (2006.01); A61B 5/00 (2006.01); A61B 5/145 (2006.01); A61M 5/00 (2006.01); A61N 1/32 (2006.01); A61B 17/00 (2006.01); A61B 18/00 (2006.01); A61B 18/12 (2006.01)
CPC A61B 18/14 (2013.01) [A61B 5/14532 (2013.01); A61B 5/14539 (2013.01); A61B 5/14546 (2013.01); A61B 5/4839 (2013.01); A61B 5/4848 (2013.01); A61B 18/1477 (2013.01); A61M 5/00 (2013.01); A61N 1/325 (2013.01); A61N 1/327 (2013.01); A61B 2017/00061 (2013.01); A61B 2017/00159 (2013.01); A61B 2018/00577 (2013.01); A61B 2018/00732 (2013.01); A61B 2018/00821 (2013.01); A61B 2018/00875 (2013.01); A61B 2018/126 (2013.01); A61M 2202/097 (2013.01); A61M 2205/054 (2013.01)] 15 Claims
OG exemplary drawing
 
1. A method of treating a tumor in a patient, the method comprising:
ablating the tumor, including applying an energy to the tumor sufficient to cause destruction of a cell membrane of cells of the tumor and spillage of intracellular components and antigens into an extracellular space; and
administering to the patient intratumorally a composition comprising a combination of at least two immune checkpoint inhibitors and an immunomodulatory agent, each being present in a therapeutically effective amount, wherein the at least two immune checkpoint inhibitors are a CTLA-4 inhibitor and a PD-1 inhibitor.